Todd Wider Net Worth

The estimated Net Worth of Todd Wider is at least $3.72 Million dollars as of 26 October 2023. Todd Wider owns over 94,844 units of Abeona Therapeutics Inc stock worth over $2,766,178 and over the last 9 years he sold ABEO stock worth over $787,408. In addition, he makes $170,195 as Independent Director at Abeona Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Todd Wider ABEO stock SEC Form 4 insiders trading

Todd has made over 10 trades of the Abeona Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 94,844 units of ABEO stock worth $91,050 on 26 October 2023.

The largest trade he's ever made was exercising 321,345 units of Abeona Therapeutics Inc stock on 17 February 2021 worth over $411,322. On average, Todd trades about 34,892 units every 125 days since 2015. As of 26 October 2023 he still owns at least 494,844 units of Abeona Therapeutics Inc stock.

You can see the complete history of Todd Wider stock trades at the bottom of the page.

Todd Wider biography

Dr. Todd Wider M.D. serves as Independent Director of the Company. Dr. Wider became a director in May 2015 and serves as a member of the Audit Committee and Compensation Committee. Dr. Wider is a surgeon and has served as consultant to numerous entities in the biotechnology space. Dr. Wider holds an M.D. from Columbia College of Physicians and a B.A. from Princeton University. Dr. Wider’s qualifications to serve our Board include his biotechnology expertise as well as his experience as a surgeon.

What is the salary of Todd Wider?

As the Independent Director of Abeona Therapeutics Inc, the total compensation of Todd Wider at Abeona Therapeutics Inc is $170,195. There are 4 executives at Abeona Therapeutics Inc getting paid more, with Christine Silverstein having the highest compensation of $1,000,220.

How old is Todd Wider?

Todd Wider is 55, he's been the Independent Director of Abeona Therapeutics Inc since 2015. There are 1 older and 7 younger executives at Abeona Therapeutics Inc. The oldest executive at Abeona Therapeutics Inc is Jon Voss, 61, who is the VP & Head of Quality.

What's Todd Wider's mailing address?

Todd's mailing address filed with the SEC is C/O ASP ISOTOPES INC., 601 PENNSYLVANIA AVENUE NW, SUITE 900, WASHINGTON, DC, DC, 20004.

Insiders trading at Abeona Therapeutics Inc

Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.

What does Abeona Therapeutics Inc do?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Complete history of Todd Wider stock trades at Abeona Therapeutics Inc, ARYA Sciences Acquisition Corp III, and Aspire Real Estate Investors

Abeona Therapeutics Inc executives and stock owners

Abeona Therapeutics Inc executives and other stock owners filed with the SEC include:

• Christine Silverstein,
  Director
• Dr. Brendan M. O'Malley J.D., Ph.D.,
  Sr. VP & Gen. Counsel
• Dr. Vishwas Seshadri M.B.A., Ph.D.,
  Pres, CEO & Director
• Edward G. Carr,
  Sr. VP, CFO & Chief Accounting Officer
• Todd Wider,
  Independent Director
• Paul Mann,
  Independent Director
• Michael Amoroso,
  Chief Operating Officer
• Edward Carr,
  Principal Financial Officer, Chief Accounting Officer, Vice President
• Alison Hardgrove,
  VP of HR
• Joseph Walter Vazzano,
  CFO, Principal Financial Officer & Principal Accounting Officer
• Sofia Warner,
  Sr. Director of Investor Relations
• Jon Voss,
  VP & Head of Quality
• Scott Nogi M.B.A.,
  VP & Head of Bus. Operation
• Kristina Maximenko,
  VP of HR
• Scott Santiamo,
  Director of Corp. Communications
• Gregory Gin,
  VP of Investor Relations & Corp. Communications
• Brian Kevany Ph.D.,
  VP & Chief Technical Officer
• Mark Alvino,
  Director
• Mark J Ahn,
  Director
• Carsten Thiel,
  Chief Executive Officer
• Timothy J Miller,
  See Remarks
• George V Migausky,
  Director
• B Davis Jeffrey,
  Chief Operating Officer
• Stephen B Thompson,
  VP-Finance Chief Acctg Officer
• Capital Management, L.P.Atc...,
  
• Joao Md Siffert,
  Chief Executive Officer
• Stephen B. Howell,
  Director
• Steven H Rouhandeh,
  Director
• Shawn Tomasello,
  Director
• Stefano Buono,
  Director
• Duyne Richard B Van,
  Director
• Brian Jg Pereira,
  Executive Chairman
• Capital Partners Llc Rouhan...,
  
• Leila Alland,
  Director
• Faith L. Charles,
  Director
• Donald A. Wuchterl,
  Director
• Brendan M. O'malley,
  SVP, General Counsel
• Joseph Walter Vazzano,
  Chief Financial Officer
• Bernhardt G Zeiher,
  Director
• Eric Crombez,
  Director